Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock
PALO ALTO, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX) announced that its majority stockholder, Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today posted a supplement to its previously issued “Frequently Asked Questions” document under the “Investors” section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company held by Sorrento.
The supplement to the FAQs provides notice regarding the Depository Trust and Clearing Corporation’s removal of the contra-CUSIP on Scilex common stock that was distributed as a dividend to Sorrento’s stockholders and provides notice to brokerage firms, banks, dealers and similar organizations listed therein that a dividend confirmation had previously been distributed to such firms by Scilex’s transfer agent and requests that such firms contact Scilex’s transfer agent if they have not received such confirmation. The supplement also reiterates a question related to issues that may arise with respect to the dividend in connection with short positions in Sorrento common stock.
The supplement to the FAQs and related annex are included in this press release and can also be found Scilex’s website https://www.scilexholding.com/investors/faqs/
SUPPLEMENT TO
FREQUENTLY ASKED QUESTIONS
REGARDING THE DIVIDEND OF SCILEX HOLDING COMPANY COMMON STOCK BY SORRENTO THERAPEUTICS, INC.
This supplement is a supplement to the Frequently Asked Questions Regarding the Dividend of Scilex Holding Company Common Stock by Sorrento Therapeutics, Inc. (Sorrento) that was issued by Sorrento on January 29, 2023 (the FAQ), a copy of which can be found under the “Investors” section of its website at www.sorrentotherapeutics.com.
This supplement is being issued to update and supplement the information in the FAQ to notify investors regarding certain matters relating to the dividend and reiterate certain questions and answers from the FAQ. Capitalized terms used in this supplement shall have their respective meetings set forth in the FAQ.
NOTICE OF REMOVAL OF CONTRA-CUSIP BY DTCC
Effective as of February 2, 2023, the Depository Trust and Clearing Corporation has removed the “contra-CUSIP” that it had previously imposed on the Dividend Stock. Any shares of Dividend Stock held by your brokerage firm, bank, dealer or other similar organization for your benefit now bear only Scilex’s CUSIP number, which is 80880W106. If you are entitled to receive Dividend Stock, please contact your brokerage firm, bank, or other similar organization immediately to confirm that the CUSIP number appears on your brokerage statement with respect to your Dividend Stock.
NOTICE TO BROKERAGE FIRMS, BANKS, DEALERS AND OTHER SIMILAR ORGANIZATIONS
If the name of your firm, bank or other similar organization is set forth on Annex B of the FAQ, which Annex B is repeated below for convenience, and your firm, bank or similar organization has not received the Dividend Confirmation that was mailed to your firm, bank or similar organization, please contact Scilex’s transfer agent immediately to obtain a copy of the Dividend Confirmation. Scilex’s transfer agent’s contact information is as follows:
Continental Stock Transfer & Trust Company
Telephone Number: 800-509-5586
Email Address: cstmail@continentalstock.com
Several major brokers have confirmed to Sorrento and Scilex that they are adding the Scilex share positions to the individual brokerage accounts of Sorrento shareholders receiving the Dividend Stock
SUPPLEMENTAL QUESTION AND ANSWER
Q: If I loaned my shares of Sorrento common stock to short sellers or any other party as of the Record Date, am I still entitled to receive Dividend Stock as of the Payment Date?
A: Only Record Holders as of the Record Date are entitled to receive the Dividend Stock. If you were the Record Holder as of the Record Date and are entitled to receive the Dividend Stock, but have not received the Dividend Stock, you may be entitled to receive Dividend Stock from the short seller or other party who borrowed your shares of Sorrento common stock, whether through the lending programs implemented by your brokerage firm, bank, dealer and other similar organization or otherwise. If you were a Record Holder as of the Record Date and have not received your Dividend Stock, please consult with your financial advisor, broker or other agent immediately to determine how to receive your Dividend Stock.
Annex B
Broker List
Broker Name | Broker Address |
| Broker Name | Broker Address |
ABN AMRO CLEARING CHICAGO LLC | 175 WEST JACKSON BLVD. |
| Albert Fried & Company LLC | 45 BROADWAY, 24TH FLOOR |
AMALGAMATED BANK | 275 7TH AVENUE |
| AMERICAN ENTERPRISE INVESTMENT SERVICES INC. | 682 AMERIPRISE FINANCIAL CENTER |
APEX CLEARING CORPORATION | 2 GATEWAY CENTER 283-299 MARKET ST |
| BANK OF AMERICA, NA/GWIM TRUST OPERATIONS | 901 MAIN STREET |
BANK OF NEW YORK MELLON | 111 SANDERS CREEK PARKWAY 2ND FLOOR |
| BARCLAYS CAPITAL INC. | DTC CUSTODY PARTICIPANT- NY WINDOW -570 WASHINGTON BLVD (ATTN: ROSA HICKS-MILLER OR ROBERT MENDEZ |
BARCLAYS CAPITAL INC. | DTC CUSTODY PARTICIPANT- NY WINDOW -570 WASHINGTON BLVD (ATTN: ROSA HICKS-MILLER OR ROBERT MENDEZ |
| BMO CAPITAL MARKETS CORP. | 3 2ND STREET |
BMO HARRIS BANK NA/TRUST | 11270 W PARK PL |
| BMO Nesbitt Burns Inc., Toronto | 250 YONGE STREET, 7TH FLOOR |
BNP PARIBAS, NEW YORK BRANCH/BNP PARIBAS PRIME BROKERAGE CUSTODIAN | 100 WEST 33RD STREET |
| BNP PARIBAS, NEW YORK BRANCH/BNP PARIBAS PRIME BROKERAGE CUSTODIAN | 100 WEST 33RD STREET |
BNY MELLON | PO BOX 392002 |
| BNY MELLON/WEALTH MANAGEMENT | 1 FREEDOM VALLEY DRIVE |
BNYMELLON | 111 SANDERS CREEK PARKWAY 2ND FLOOR |
| BNYMELLON/RE BARCLAYS CAPITAL SECURITIES LTD. | ONE WALL STREET |
BNYMELLON/RE CACEIS BANK LUXEMBOURG | 500 Grant St. |
| BNYMELLON/RE CACEIS BANK, NETHERLANDS | 111 SANDERS CREEK PARKWAY |
BNYMELLON/RE CHARLES STANLEY AND COMPANY, LIMITED | 111 SANDERS CREEK PARKWAY 2ND FLOOR |
| BNYMELLON/RE ETF - ISHARES DTC/NSCC | 111 SANDERS CREEK PARKWAY |
BNYMELLON/RE WINTERFLOOD SECURITIES LTD | 500 Grant St. |
| BOFA | 4804 Deer Lake Drive East |
BOFA | 4804 Deer Lake Drive East |
| BOFA SECURITIES INC | 4804 Deer Lake Drive East |
BROWN BROTHERS HARRIMAN & CO. | 140 BROADWAY |
| BROWN BROTHERS HARRIMAN & CO./ETF | 140 BROADWAY |
CALDWELL SECURITIES LTD./CDS** | 55 UNIVERSITY AVENUE |
| CANACCORD GENUITY CORP. | 609 GRANVILLE ST |
CANTOR, FITZGERALD & CO. | 135 E 57TH ST 5TH FL |
| CDS CLEARING AND DEPOSITORY SERVICES INC. | 100 ADELAIDE STREET WEST |
CETERA INVESTMENT SERVICES LLC | 400 FIRST STREET SOUTH, SUITE 300 |
| CHARLES SCHWAB & CO., INC. | 211 MAIN STREET |
CI INVESTMENT SERVICES INC. | 199 BAY STREET |
| CIBC WORLD MARKETS INC./CDS** | 161 BAY STREET 10 FL |
CITIBANK, N.A./ETF | 3800 CITIGROUP CENTER |
| CITIBANK, NATIONAL ASSOCIATION | 3800 CITIBANK CENTER TAMPA |
CITIGROUP GLOBAL MARKETS, INC. | 580 CROSSPOINT PARKWAY |
| CLEAR STREET LLC | 4 World Trade Center, 45th Floor |
CLEARSTREET IO | 55 BROADWAY (SUITE 2102) |
| COMMERCE BANK | 922 WALNUT STREET |
COR CLEARING LLC | 9300 UNDERWOOD AVE |
| Credential Securities Inc. | 800-1111 WEST GEORGIA STREET |
CREST INTERNATIONAL NOMINEES LIMITED | 33 CANNON STREET |
| CURVATURE SECURITIES, LLC | 39 MAIN STREET |
D.A. DAVIDSON & CO. | 8 3RD STREET NORTH |
| DEPOSITO CENTRAL DE VALORES S.A., DEPOSITO DE VALORES | AVENIDA APOQUINDO # 4001 |
DESJARDINS SECURITIES INC. | 1253 McGill College |
| DEUTSCHE BANK AG NY/US CUSTODY | 1251 Avenue Of The Americas |
DEUTSCHE BANK SECURITIES INC. | 60 WALL STREET |
| DRIVEWEALTH, LLC | 15 EXCHANGE PLACE |
E*TRADE CLEARING LLC | HARBORSIDE FINANCIAL CENTER |
| EDWARD D. JONES & CO., L.P. | 12555 MANCHESTER ROAD |
EDWARD D. JONES & CO., L.P. | 201 PROGRESS PARKWAY |
| FIDELITY CLEARING CANADA ULC/CDS** | 483 BAY ST. |
FIFTH THIRD BANK | 5001 KINGSLEY DRIVE |
| FOLIO INVESTMENTS, INC. | 8180 GREENSBORO DRIVE |
FUTU CLEARING INC. | 12750 Merit Drive |
| GMP SECURITIES L.P. | 145 KING STREET WEST, SUITE 300 |
GOLDMAN, SACHS & CO. LLC | 222 SOUTH MAIN STREET |
| HAYWOOD SECURITIES INC./CDS** | 200 BURRARD ST |
HILLTOP SECURITIES INC. | 1201 ELM ST. |
| HRT FINANCIAL LLC | 150 GREENWICH STREET (ATTN: SETTLEMENT) FOUR WORLD TRADE CENTER |
HSBC BANK USA, NA/HSBC CUSTODY & CLEARING SERVICES FOR STOCK LOAN | 452 FIFTH AVENUE |
| HSBC BANK USA, NATIONAL ASSOCIATION | 452 FIFTH AVENUE |
INTERACTIVE BROKERS LLC | 2 PICKWICK PLAZA |
| J.P. MORGAN CHASE BANK NA/FBO BLACKROCK CTF | 1111 POLARIS PARKWAY |
J.P. MORGAN CLEARING CORP. | FOUR CHASE METROTECH CENTER |
| JANNEY MONTGOMERY SCOTT LLC | 1717 ARCH STREET |
JEFFERIES LLC | 101 HUDSON STREET, 11th Floor |
| JPMORGAN CHASE BANK, NATIONAL ASSOCIATION | FOUR CHASE METROTECH CENTER |
JPMORGAN CHASE BANK/EUROCLEAR BANK | FOUR CHASE METROTECH CENTER |
| JPMORGAN CHASE BANK/IA | FOUR CHASE METROTECH CENTER |
KEYBANK NATIONAL ASSOCIATION | 4900 TIEDEMAN RD |
| LAURENTIAN BANK SECURITIES INC. | 1981 MCGILL COLLEGE AVE. |
LPL FINANCIAL LLC | 4707 EXECUTIVE DRIVE |
| MANUFACTURERS AND TRADERS TRUST COMPANY | ONE M&T PLAZA |
MANULIFE SECURITIES INCORPORATED | 1235 NORTH SERVICE ROAD WEST |
| MARSCO INVESTMENT CORPORATION | 101 EISENHOWER PARKWAY |
MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED | 4804 Deer Lake Drive East |
| MIRAE ASSET SECURITIES (USA) INC./STOCK LOAN CONDUIT ACCOUNT | 810 SEVENTH AVE |
MIRAE ASSET SECURITIES (USA), INC. | 810 SEVENTH AVE |
| MITSUBISHI UFJ TRUST & BANKING CORPORATION, NEW YORK BRANCH | 280 PARK AVE |
Morgan Stanley | 1300 THAMES STREET |
| MORGAN STANLEY & CO. LLC | 1300 THAMES ST. |
MORGAN STANLEY SMITH BARNEY LLC | 1 NEW YORK PLAZA |
| MURIEL SIEBERT & CO., INC. | 77 SUMMER STREET |
NATIONAL FINANCIAL SERVICES LLC | 499 WASHINGTON BOULEVARD |
| NBCN INC. | 1010 rue De La Gauchetière |
NOMURA INTERNATIONAL TRUST COMPANY | 309 WEST 49TH STREET |
| ODLUM BROWN LIMITED | 250 HOWE STREET |
OPPENHEIMER & CO. INC. | 85 BROAD STREET |
| PERSHING LLC | 1 PERSHING PLAZA |
PHILLIP CAPITAL INC. | 141 W. JACKSON BLVD. SUITE 3050 |
| PI FINANCIAL CORP. | 666 BURRARD ST |
PNC BANK, NATIONAL ASSOCIATION | 4100 W 150TH STREET |
| PRINCIPAL BANK | 711 HIGH STREET |
QUESTRADE INC./CDS** | 5650 YONGE ST., |
| Raymond James & Associates, Inc. | 880 CARILLON PKWY |
RAYMOND JAMES LTD. | 925 WEST GEORGIA STREET |
| RBC CAPITAL MARKETS, LLC | 60 SOUTH 6TH ST. |
RBC DOMINION SECURITIES INC | 21 COMMERCE COURT SOUTH |
| RELIANCE TRUST COMPANY | 1100 ABERNATHY RD. |
RELIANCE TRUST COMPANY | 4900 W. BROWN DEER RD |
| ROBERT W. BAIRD & CO. INCORPORATED | 777 E WISCONSIN AVE |
ROBINHOOD SECURITIES, LLC | 500 COLONIAL CENTER PARKWAY |
| SAFRA SECURITIES LLC | 546 5TH AVENUE |
SCOTIA CAPITAL (USA) INC. | 150 KING STREET W |
| SEI PRIVATE TRUST COMPANY | 1 FREEDOM VALLEY DRIVE |
SEI PRIVATE TRUST COMPANY | 1 FREEDOM VALLEY DRIVE |
| SG AMERICAS SECURITIES, LLC | 480 WASHINGTON BLVD. |
SSB - BLACKROCK INSTITUTIONAL TRUST | 50 California Street |
| SSB - TRUST CUSTODY | 30 ADELAIDE ST EAST |
SSB&T CO/CLIENT CUSTODY SERVICES | 1776 HERITAGE DRIVE |
| STATE STREET BANK & TRUST CO | 16 WALL STREET |
STATE STREET BANK & TRUST COMPANY / ISHARES EUROPE | 1776 HERITAGE DRIVE |
| STATE STREET BANK & TRUST/STATE STREET TOTALETF | 1776 Heritage Drive |
STATE STREET BANK AND TRUST COMPANY | 30 ADELAIDE ST EAST |
| STIFEL, NICOLAUS & COMPANY, INCORPORATED | 501 N BROADWAY |
STONEX FINANCIAL INC. | 2 PERIMETER PARK SOUTH |
| TD AMERITRADE CLEARING, INC. | 200 S 108TH AVE |
TD WATERHOUSE CANADA INC | 77 BLOOR STREET WEST |
| TEXAS TREASURY SAFEKEEPING TRUST COMPANY | 208 E 10TH ST |
THE BANK OF NEW YORK MELLON | 500 GRANT STREET |
| THE HUNTINGTON NATIONAL BANK | 7 EASTON OVAL EA4E62 |
THE NORTHERN TRUST COMPANY | 333 South Wabash Ave, 32nd Floor |
| TRADESTATION SECURITIES, INC. | 120 RIVERSIDE PLAZA |
U.S. BANCORP INVESTMENTS, INC. | 60 LIVINGSTON AVE |
| U.S. BANK N.A./ETF | 1555 N RIVER CENTER DRIVE |
U.S. BANK NATIONAL ASSOCIATION | 1555 NORTH RIVERCENTER DRIVE, SUITE 302 |
| UBS AG | 480 WASHINGTON BLVD. |
UBS FINANCIAL SERVICES INC. | 1000 HARBOR BOULEVARD |
| UBS SECURITIES LLC | 677 WASHINGTON BLVD |
UMB BANK, NATIONAL ASSOCIATION | 928 GRAND BLVD |
| VANGUARD MARKETING CORPORATION | 100 VANGUARD BLVD |
VELOCITY CLEARING, LLC | 1301 Route 36 |
| VELOX CLEARING LLC | 2400 E. KATELLA AVENUE |
VIRTU AMERICAS LLC | ONE LIBERTY PLAZA, 165 BROADWAY |
| VISION FINANCIAL MARKETS LLC | 4 HIGH RIDGE PARK |
WEDBUSH SECURITIES INC | 1000 WILSHIRE BLVD |
| WEDBUSH SECURITIES INC. | 1000 WILSHIRE BLVD. |
WELLS FARGO BANK, N.A./SIG | 733 MARQUETTE AVE 4TH FLOOR |
| WELLS FARGO CLEARING SERVICES LLC | 1 NORTH JEFFERSON |
WELLS FARGO SECURITIES, LLC | 1525 WEST W T HARRIS BLVD |
| WILSON-DAVIS & CO., INC. | 236 SOUTH MAIN STREET |
About Scilex Holding Company
Scilex Holding Company, a majority-owned by Sorrento Therapeutics, Inc., is an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life. Results from the Phase III Pivotal Trial C.L.E.A.R Program for SEMDEXA™, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. Scilex has applied for breakthrough therapy designation and expects to seek priority review for SEMDEXA™ for the treatment of sciatica. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with moderate to severe pain. Scilex launched its first commercial product in October 2018, in-licensed a commercial product in June 2022, and is developing its late-stage pipeline, which includes a pivotal Phase 3 candidate and one Phase 2 and one Phase 1 candidate. Its commercial product, ZTlido® (lidocaine topical system) 1.8%, or ZTlido®, is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. Scilex in-licensed the exclusive right to commercialize Gloperba® (colchicine USP) oral solution, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S. Scilex is planning to commercialize Gloperba® in 2023 and is well-positioned to market and distribute the product. Scilex’s three product candidates are SP-102 (injectable dexamethasone sodium phosphate viscous gel product containing 10 mg dexamethasone), or SEMDEXA™, a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, with FDA Fast Track status; SP-103 (lidocaine topical system) 5.4%, a Phase 2, triple-strength formulation of ZTlido®, for the treatment of low back pain, with FDA Fast Track status; and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule, for the treatment of chronic pain, fibromyalgia that has completed multiple Phase 1 trial programs and expected to initiate Phase 2 trials this year. For further information regarding the SP-102 Phase 3 efficacy trial, see NCT identifier NCT03372161 – Corticosteroid Lumbar Epidural Analgesia for Radiculopathy – Full Text View – ClinicalTrials.gov.
Scilex Holding Company is headquartered in Palo Alto, California, with operations in both Palo Alto and San Diego, California. For further information please visit www.scilexholding.com.
About Sorrento Therapeutics, Inc.
Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as Abivertinib, next-generation tyrosine kinase inhibitors (“TKIs”), fully human antibodies (“G-MAB™ library”), immuno-cellular therapies (“DAR-T™”), antibody-drug conjugates (“ADCs”), and oncolytic virus (“Seprehvec™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including STI-1558, COVI-MSC™; and diagnostic test solutions, including COVIMARK™.
Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a TRPV1 agonist, non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of postherpetic neuralgia (PHN). RTX has been cleared for a Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients. Positive final results from the Phase III Pivotal Trial C.L.E.A.R. Program for SEMDEXA™, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. ZTlido® was approved by the FDA on February 28, 2018.
For more information visit www.sorrentotherapeutics.com.
Contacts:
For Scilex Holding Company
Jaisim Shah
Chief Executive Officer
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310
Email: jshah@scilexpharma.com
Website: www.sorrentotherapeutics.com and www.scilexholding.com
Investors and Media Contact:
Elizabeth Czerepak
Email: mediarelations@sorrentotherapeutics.com
Website: www.sorrentotherapeutics.com
Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.
G-MAB™, DAR-T™, Seprehvec™, SOFUSA™, COVI-MSC™, COVIMARK™, Ovydso™ and Fujovee™ are trademarks of Sorrento Therapeutics, Inc.
SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.
ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.
Gloperba® is an exclusive, transferable license to use the trademark by Scilex Holding Company.
All other trademarks are the property of their respective owners.
© 2023 Sorrento Therapeutics, Inc. All Rights Reserved.
